Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Euro Health Officials Restrict Potiga Prescriptions on Skin, Eye Discoloration Side Effect Worries

Filed June 3rd, 2013 Joshua Sophy

Health authorities in Europe have severely restricted access to the anti-seizure medication Potiga (sold in Europe as Trobalt) after it was linked to serious side effects.

According to a report at PMLive.com, Europe’s Committee for Medicinal Products for Human Use (CHMP) has relegated Potiga (Trobalt) to the point that it should only be considered as a means of preventing seizures when all other available options have not worked. CHMP works in a similar fashion to an advisory committee working with federal health officials here.

The move follows a similar measure taken by the U.S. Food and Drug Administration (FDA) last month, according to the PMLive.com report. Potiga (Trobalt) has been linked to severe skin discolorations as well as a discoloration of the retina. Retinal discoloration could result in impaired vision for some victims, according to the PMLive.com report. Victims of this skin discoloration may also acquire the condition in the skin, nails, lips, and in eye tissue.

CHMP warns that any new patient receiving Potiga (Trobalt) should undergo a comprehensive eye exam at the start of the treatment and every six months while continuing to take the drug.

Severely restricting access to Potiga (Trobalt) only means people who suffer epileptic seizures must choose another drug. According to our reports, that could be a dangerous choice as other epilepsy drugs have been linked to other dangerous side effects. In fact, in 2008, the FDA warned that people taking epilepsy drugs were twice as likely to suffer from suicidal thoughts or behaviors as people taking a placebo drug.

Other popular epilepsy drugs sold in the U.S. include Tegretol, Neurontin, Keppra, Lyrica, Topamax, and Depakote.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!